Philadelphia Business Journal’s Innovation Sector Celebrates iECURE as PHL Inno’s 2024 Fire Awards Honoree
The Fire Awards aim to celebrate the most promising businesses and individuals driving success and innovation locally in Greater Philadelphia.
President’s Sustainability Prize Winner Shinkei Systems Aims to Upend the Fish-Harvesting Industry
The 2022 President’s Sustainability Prize winner Shinkei Systems was recognized in a recent article by Tech Crunch for its role in changing the seafood industry.
EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Ascidian Therapeutics Partners with Roche for Discovery and Development of RNA Therapeutics Targeting Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Sixth Annual Pennovation Accelerator Pitch Day
ch of the nine Philadelphia-based cohort companies presented a 5-minute pitch to a live audience, followed by questions and feedback from a panel of judges.
Development of RNA Therapeutics Targeting Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
Meet Jochi, the 2024 President’s Innovation Prize Winning Team Focused on Making Life Easier for Students with Learning Differences
The platform, called Jochi, which has further evolved since its conception in 2020, integrates easily into existing school systems and provides educators with tools to support these students.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.